Suzuki, K.; Fujimori, Y.; Sakai, C.; Tsuchiya, H.; Koroki, Y.
Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan. Cancers 2025, 17, 1389.
https://doi.org/10.3390/cancers17091389
AMA Style
Suzuki K, Fujimori Y, Sakai C, Tsuchiya H, Koroki Y.
Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan. Cancers. 2025; 17(9):1389.
https://doi.org/10.3390/cancers17091389
Chicago/Turabian Style
Suzuki, Kazuhito, Yuma Fujimori, Chika Sakai, Hiroaki Tsuchiya, and Yosuke Koroki.
2025. "Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan" Cancers 17, no. 9: 1389.
https://doi.org/10.3390/cancers17091389
APA Style
Suzuki, K., Fujimori, Y., Sakai, C., Tsuchiya, H., & Koroki, Y.
(2025). Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan. Cancers, 17(9), 1389.
https://doi.org/10.3390/cancers17091389